MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • MDS Virtual Congress 2020

    Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Effect on MDS-UPDRS Part III Subdomains

    M. Siddiqui, V. Evidente, P. Bhargava, B. Navia, E. Pappert (Winston-Salem, NC, USA)

    Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) as an on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD) on MDS-UPDRS Part…
  • MDS Virtual Congress 2020

    Characterization of the pattern of daily motor fluctuations in Parkinson’s disease patients based on home diaries

    R. Hauser, W. Poewe, J. Ferreira, A. Lees, G. Liang, M. Fonseca, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Tampa, FL, USA)

    Objective: Home diary-based representation of patients’ daily motor status. Background: Parkinson’s disease (PD) patients are often in their best clinical state when attending medical appointments.…
  • MDS Virtual Congress 2020

    Targeting the Receptor of Glial Cell Line-Derived Neurotrophic factor to treat Parkinson’s Disease

    Y. Sidorova, A. Mahato, M. Saarma (Helsinki, Finland)

    Objective: Our goal is to develop small molecules which support and restore nigrostriatal dopamine neurons by activation of glial cell line-derived-neurotrophic factor (GDNF) receptors. Background:…
  • MDS Virtual Congress 2020

    Association between prediagnostic symptoms and patterns of treatment initiation in people with Parkinson´s disease in the United Kingdom

    L. Rutten-Jacobs, S. Roumpanis, Y. Liu, P. Coloma (Basel, Switzerland)

    Objective: To explore the association between prediagnostic symptoms and treatment initiation in people with Parkinson´s disease (PD) Background: Prediagnostic symptoms in people with PD may…
  • MDS Virtual Congress 2020

    Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings

    F. Stocchi, C. Olanow, E. Peckham, F. Agbo, Y. Chiu, K. Sciarappa, B. Navia (Rome, Italy)

    Objective: Evaluate if dose optimization (DO) of apomorphine sublingual film (APL-130277; APL) can achieve improved FULL “ON” response in patients with Parkinson’s disease (PD) and…
  • MDS Virtual Congress 2020

    An Analysis of Parkinson’s Disease Medication Treatment Patterns among Medicaid Patients

    M. Johnsrud, K. Richards, R. Sasane, M. Leoni, S. Arcona (Austin, TX, USA)

    Objective: To describe patient demographic and medication utilization patterns within a state Medicaid program for patients diagnosed with Parkinson’s disease (PD). Background: Little is known…
  • MDS Virtual Congress 2020

    Efficacy and safety of istradefylline in Parkinson’s disease patients with postural abnormality: Results from a multicenter, open-label study in Japan

    M. Takahashi, T. Shimokawa, J. Koh, T. Takeshima, H. Yamashita, Y. Kajimoto, A. Mori, H. Ito (Osaka, Japan)

    Objective: To investigate the efficacy and safety of istradefylline for the treatment of postural abnormality in patients with Parkinson’s disease (PD). Background: Postural abnormality in…
  • MDS Virtual Congress 2020

    Preclinical pharmacology and early clinical development of dopamine D1 positive allosteric modulators (D1PAMs) with therapeutic potential for neuropsychiatric disorders

    K. Svensson, H. Meltzer, K. Biglan (Indianapolis, IN, USA)

    Objective: The objective was to characterize novel dopamine D1PAMs pre-clinically in behavioral and neurochemical models and in phase 1 human studies in healthy volunteers and…
  • MDS Virtual Congress 2020

    Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial

    C. Tanner, D. Chernick, A. Formella (San Francisco, CA, USA)

    Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…
  • MDS Virtual Congress 2020

    Effect of opicapone and entacapone on daily pattern of motor fluctuations in Parkinson’s disease patients

    A. Lees, O. Rascol, J. Ferreira, O. Klepitskaya, M. Fonseca, D. Magalhães, J.F Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on daily pattern of motor fluctuations. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 32
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Unusual prolonged survival in multiple system atrophy: A case report
  • An atypical and interesting feature of Parkinson´s disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley